PPD shareholders approve $3.9 billion acquisition
This article was originally published in Scrip
Shareholders of the CRO PPD have approved the $3.9 billion acquisition by the private equity companies Carlyle Group and Hellman & Friedman. Approximately 96.4% of shareholders voted in favour, and will receive $33.25 in cash for each share of the company's common stock they own.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"